Dupont Capital Management Corp acquired a new stake in shares of Pharmerica Corporation (NYSE:PMC) during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 45,000 shares of the company’s stock, valued at approximately $1,319,000. Dupont Capital Management Corp owned about 0.14% of Pharmerica Corporation as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. The Manufacturers Life Insurance Company boosted its stake in Pharmerica Corporation by 0.3% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 23,228 shares of the company’s stock worth $610,000 after buying an additional 71 shares during the last quarter. Los Angeles Capital Management & Equity Research Inc. boosted its stake in Pharmerica Corporation by 0.9% in the 2nd quarter. Los Angeles Capital Management & Equity Research Inc. now owns 11,614 shares of the company’s stock worth $305,000 after buying an additional 100 shares during the last quarter. Capstone Asset Management Co. raised its holdings in shares of Pharmerica Corporation by 0.9% in the 2nd quarter. Capstone Asset Management Co. now owns 16,041 shares of the company’s stock worth $421,000 after purchasing an additional 150 shares during the period. Louisiana State Employees Retirement System raised its holdings in shares of Pharmerica Corporation by 1.6% in the 2nd quarter. Louisiana State Employees Retirement System now owns 12,700 shares of the company’s stock worth $333,000 after purchasing an additional 200 shares during the period. Finally, Arizona State Retirement System raised its holdings in shares of Pharmerica Corporation by 1.2% in the 2nd quarter. Arizona State Retirement System now owns 16,216 shares of the company’s stock worth $426,000 after purchasing an additional 200 shares during the period. 86.01% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: This report was first published by Watch List News and is owned by of Watch List News. If you are viewing this report on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark laws. The legal version of this report can be accessed at https://www.watchlistnews.com/dupont-capital-management-corp-acquires-new-position-in-pharmerica-corporation-pmc/1692883.html.

A number of research firms have recently commented on PMC. Zacks Investment Research downgraded Pharmerica Corporation from a “buy” rating to a “hold” rating in a report on Wednesday, October 4th. ValuEngine downgraded Pharmerica Corporation from a “buy” rating to a “hold” rating in a report on Friday, September 22nd. Barrington Research downgraded Pharmerica Corporation from an “outperform” rating to an “underperform” rating in a report on Thursday, August 3rd. KeyCorp downgraded Pharmerica Corporation to an “overweight” rating in a report on Tuesday, August 8th. Finally, Credit Suisse Group downgraded Pharmerica Corporation from an “outperform” rating to a “neutral” rating and raised their price objective for the stock from $29.00 to $29.25 in a report on Friday, August 4th. They noted that the move was a valuation call. Two research analysts have rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of $30.50.

Shares of Pharmerica Corporation (PMC) opened at $29.10 on Friday. The company has a market capitalization of $905.56, a PE ratio of 15.24, a P/E/G ratio of 1.27 and a beta of 0.82. The company has a current ratio of 2.57, a quick ratio of 1.79 and a debt-to-equity ratio of 0.75. Pharmerica Corporation has a twelve month low of $22.00 and a twelve month high of $29.50.

Pharmerica Corporation Profile

Institutional Ownership by Quarter for Pharmerica Corporation (NYSE:PMC)

Receive News & Ratings for Pharmerica Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharmerica Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.